Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-25-006997
Filing Date
2025-01-27
Accepted
2025-01-27 16:13:14
Documents
16
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K ea0228725-10ka1_citius.htm   iXBRL 10-K/A 178815
2 CERTIFICATION ea022872501ex31-3_citius.htm EX-31.3 5669
3 CERTIFICATION ea022872501ex31-4_citius.htm EX-31.4 5466
4 COMPENSATION RECOVERY POLICY ea022872501ex97-1_citius.htm EX-97.1 42466
  Complete submission text file 0001213900-25-006997.txt   443335

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20240930.xsd EX-101.SCH 3063
6 XBRL LABEL FILE ctxr-20240930_lab.xml EX-101.LAB 32605
7 XBRL PRESENTATION FILE ctxr-20240930_pre.xml EX-101.PRE 16880
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0228725-10ka1_citius_htm.xml XML 6902
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-K/A | Act: 34 | File No.: 001-38174 | Film No.: 25559175
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)